Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Capital Expenditures: 2019-2025

Historic Capital Expenditures for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $470,000.

  • BridgeBio Pharma's Capital Expenditures rose 243.07% to $470,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 15.90%. This contributed to the annual value of $933,000 for FY2024, which is 28.56% down from last year.
  • BridgeBio Pharma's Capital Expenditures amounted to $470,000 in Q3 2025, which was up 82.88% from $257,000 recorded in Q2 2025.
  • BridgeBio Pharma's Capital Expenditures' 5-year high stood at $6.5 million during Q3 2021, with a 5-year trough of $47,000 in Q4 2024.
  • In the last 3 years, BridgeBio Pharma's Capital Expenditures had a median value of $337,000 in 2025 and averaged $300,273.
  • As far as peak fluctuations go, BridgeBio Pharma's Capital Expenditures soared by 1,077.05% in 2021, and later crashed by 89.20% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Capital Expenditures stood at $2.5 million in 2021, then plummeted by 68.41% to $801,000 in 2022, then tumbled by 45.69% to $435,000 in 2023, then plummeted by 89.20% to $47,000 in 2024, then soared by 243.07% to $470,000 in 2025.
  • Its Capital Expenditures stands at $470,000 for Q3 2025, versus $257,000 for Q2 2025 and $337,000 for Q1 2025.